معلومات عن هذه الحلقة
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and off-label use of precision medicine is damaging precision medicine in American clinics, compared to hurdles in data access and funding facing European researchers.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and off-label use of precision medicine is damaging precision medicine in American clinics, compared to hurdles in data access and funding facing European researchers.
الإنجليزية
الولايات المتحدة
النص 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
البحث في الحلقات الماضية
البحث في الحلقات السابقة من IBCD 2016.
حلقات أخرى في هذا البودكاست
Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials.
He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment.
She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays.
He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
إخلاء المسؤولية: البودكاست والأعمال الفنية المضمنة في هذه الصفحة مأخوذة من ecancer.org، وهي مملوكة لمالكها وليست تابعة لشركة Listen Notes, Inc أو معتمدة منها.
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
